News

-Driving Growth Opportunities in Regenerative Medicine through Global Partnerships –

Human Life CORD Japan Inc. (President & CEO: Masamitsu Harata, Headquarters: Chuo-ku, Tokyo, hereafter “HLC”), a pioneer in developing umbilical cord–derived mesenchymal stromal cells (UC-MSCs) as regenerative medical products, has been selected as one of five presenting companies in the Startup Showcase at the “Davos of Healthcare™ Summit Tokyo 2025,” to be held on September 24, 2025, at Hotel Okura Tokyo.

The theme of this year’s Summit is “A Tri-Nation Collaboration: Building Bridges Beyond Borders in Healthcare.” Senior leaders from Japan, Saudi Arabia, and the United States will gather to share the latest technologies and insights, while engaging in discussions on international collaboration in healthcare. Policymakers, investors, healthcare professionals, and corporate leaders from around the world will convene to explore pathways toward a sustainable future in healthcare.

HLC is advancing innovative cell therapy research and development utilizing UC-MSCs. Guided by its corporate philosophy, “Cords of life, leading the future,” the Company is dedicated to addressing global healthcare challenges through regenerative medicine. At the Startup Showcase, HLC will present its research achievements and future vision, while seeking opportunities for joint research and business partnerships through international collaboration.

For more details about the Summit, please visit the official website:
https://www.c3int.org/upcoming-summits/c3-japan-davos-of-healthcare-summit-details.html

________________________________________

[Contact for Media Inquiries]
Public Relations, Human Life CORD Japan Inc.
Attn: Yuki Hayashi
TEL: +81-80-4671-0405
Email: info@humanlifecord.co